Advertisement
Position Paper| Volume 45, ISSUE 3, P335-346, February 2009

Methylated genes as new cancer biomarkers

Published:January 12, 2009DOI:https://doi.org/10.1016/j.ejca.2008.12.008

      Abstract

      Aberrant hypermethylation of promoter regions in specific genes is a key event in the formation and progression of cancer. In at least some situations, these aberrant alterations occur early in the formation of malignancy and appear to be tumour specific. Multiple reports have suggested that measurement of the methylation status of the promoter regions of specific genes can aid early detection of cancer, determine prognosis and predict therapy responses. Promising DNA methylation biomarkers include the use of methylated GSTP1 for aiding the early diagnosis of prostate cancer, methylated PITX2 for predicting outcome in lymph node-negative breast cancer patients and methylated MGMT in predicting benefit from alkylating agents in patients with glioblastomas. However, prior to clinical utilisation, these findings require validation in prospective clinical studies. Furthermore, assays for measuring gene methylation need to be standardised, simplified and evaluated in external quality assurance programmes. It is concluded that methylated genes have the potential to provide a new generation of cancer biomarkers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Duffy M.J.
        Role of tumor markers in patients with solid cancers: a critical review.
        Eur J Intern Med. 2007; 18: 175-184
        • Thomas C.M.
        • Sweep C.G.
        Serum tumor markers: past, state of the art, and future.
        Int J Biol Markers. 2001; 16: 73-86
        • Hahn W.C.
        • Weinberg R.A.
        Rules for making human tumor cells.
        New Engl J Med. 2002; 347: 1593-1603
        • Vogelstein B.
        • Kinzler K.W.
        Cancer genes and the pathways they control.
        Nat Med. 2004; 10: 789-799
        • Anker P.
        • Mulcahy H.
        • Stroun M.
        Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies?.
        Int J Cancer. 2003; 103: 149-152
        • Chin L.
        • Gray J.W.
        Translating insights from the cancer genome into clinical practice.
        Nature. 2008; 452: 553-563
        • Sidransky D.
        Nucleic acid-based methods for the detection of cancer.
        Science. 1997; 278: 1054-1059
        • Esteller M.
        Epigenetics in cancer.
        New Engl J Med. 2008; 358: 1148-1159
        • Jones P.A.
        • Baylin S.B.
        The epigenomics of cancer.
        Cell. 2007; 128: 683-692
        • Laird P.W.
        The power and the promise of DNA methylation markers.
        Nat Rev Cancer. 2003; 3: 253-266
        • Widschwendter M.
        • Jones P.A.
        DNA methylation and breast carcinogenesis.
        Oncogene. 2002; 21: 5462-5482
        • Costello J.F.
        • Fruhwald M.C.
        • Smiraglia D.J.
        • et al.
        Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.
        Nat Genet. 2000; 24: 132-138
        • Momparler R.L.
        Cancer epigenetics.
        Oncogene. 2003; 22: 6479-6483
        • Wong D.J.
        • Barrett M.T.
        • Stoger R.
        • et al.
        P16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
        Cancer Res. 1997; 57: 2619-2622
        • Wong D.J.
        • Paulson T.G.
        • Prevo L.J.
        • et al.
        P16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium.
        Cancer Res. 2001; 61: 8284-8289
        • Belinsky S.A.
        • Nikula K.J.
        • Palmisano W.A.
        • et al.
        Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis.
        Proc Natl Acad Sci U S A. 1998; 95: 11891-11896
        • Nuovo G.J.
        • Plaia T.W.
        • Belinsky S.A.
        • et al.
        In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis.
        Proc Natl Acad Sci USA. 1999; 96: 12754-12759
        • Esteller M.
        • Tortola S.
        • Toyota M.
        • et al.
        Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.
        Cancer Res. 2000; 60: 129-133
        • Esteller M.
        • Sparks A.
        • Toyota M.
        • et al.
        Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.
        Cancer Res. 2000; 60: 4366-4371
        • Esteller M.
        • Toyota M.
        • Sanchez-Cespedes M.
        • et al.
        Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
        Cancer Res. 2000; 60: 2368-2371
        • Fleisher A.S.
        • Esteller M.
        • Harpaz N.
        • et al.
        Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1.
        Cancer Res. 2000; 60: 4864-4868
        • Esteller M.
        • Catasus L.
        • Matias-Guiu X.
        • et al.
        HMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis.
        Am J Pathol. 1999; 155: 1767-1772
        • Brooks J.D.
        • Weinstein M.
        • Lin X.
        • et al.
        CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia.
        Cancer Epidemiol Biomarkers Prev. 1998; 7: 531-536
        • Jeronimo C.
        • Henrique R.
        • Hoque M.O.
        • et al.
        A quantitative promoter methylation profile of prostate cancer.
        Clin Cancer Res. 2004; 10: 8472-8478
        • Harder J.
        • Opitz O.G.
        • Brabender J.
        • et al.
        Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver.
        Int J Cancer. 2008; 122: 2800-2804
        • Umbricht C.B.
        • Evron E.
        • Gabrielson E.
        • et al.
        Hypermethylation of 14–3-3 sigma (stratifin) is an early event in breast cancer.
        Oncogene. 2001; 20: 3348-3353
        • Honorio S.
        • Agathanggelou A.
        • Schuermann M.
        • et al.
        Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
        Oncogene. 2003; 22: 147-150
        • Dulaimi E.
        • Hillinck J.
        • Ibanez de Caceres I.
        • et al.
        Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
        Clin Cancer Res. 2004; 10: 6189-6193
        • Feng Q.
        • Balasubramanian A.
        • Hawes S.E.
        • et al.
        Detection of hypermethylated genes in women with and without cervical neoplasia.
        J Natl Cancer Inst. 2005; 97: 273-282
        • Lafata J.E.
        • Simpkins J.
        • Lamerato L.
        • et al.
        The economic impact of false-positive cancer screens.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 2126-2132
        • Kane M.F.
        • Loda M.
        • Gaida G.M.
        • et al.
        Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.
        Cancer Res. 1997; 57: 808-811
        • Toyota M.
        • Ahuja N.
        • Suzuki H.
        • et al.
        Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype.
        Cancer Res. 1999; 59: 5438-5442
        • Eads C.A.
        • Lord R.V.
        • Wickramasinghe K.
        • et al.
        Epigenetic patterns in the progression of esophageal adenocarcinoma.
        Cancer Res. 2001; 61: 3410-3418
        • Shen L.
        • Ahuja N.
        • Shen Y.
        • et al.
        DNA methylation and environmental exposures in human hepatocellular carcinoma.
        J Natl Cancer Inst. 2002; 94: 755-761
        • Esteller M.
        • Corn P.G.
        • Baylin S.B.
        • et al.
        A gene hypermethylation profile of human cancer.
        Cancer Res. 2001; 61: 3225-3229
        • Paz M.F.
        • Fraga M.F.
        • Avila S.
        • et al.
        A systematic profile of DNA methylation in human cancer cell lines.
        Cancer Res. 2003; 63: 1114-1121
        • Hainaut P.
        • Hollstein M.
        P53 and human cancer: the first ten thousand mutations.
        Adv Cancer Res. 2000; 77: 81-137
        • Laurent-Puig P.
        • Beroud C.
        • Soussi T.
        APC gene: database of germline and somatic mutations in human tumors and cell lines.
        Nucleic Acids Res. 1998; 26: 269-270
        • Belinsky S.A.
        Gene-promoter hypermethylation as a biomarker in lung cancer.
        Nat Rev Cancer. 2004; 4: 707-717
        • Palmisano W.A.
        • Divine K.K.
        • Saccomanno G.
        • et al.
        Predicting lung cancer by detecting aberrant promoter methylation in sputum.
        Cancer Res. 2000; 60: 5954-5958
        • Kersting M.
        • Friedl C.
        • Kraus A.
        • et al.
        Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers.
        J Clin Oncol. 2000; 18: 3221-3229
        • Goessl C.
        • Krause H.
        • Muller M.
        • et al.
        Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
        Cancer Res. 2000; 60: 5941-5945
        • Goessl C.
        • Muller M.
        • Straub B.
        • et al.
        DNA alterations in body fluids as molecular tumor markers for urological malignancies.
        Eur Urol. 2002; 41: 668-676
        • Li L.C.
        • Carroll P.R.
        • Dahiya R.
        Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
        J Natl Cancer Inst. 2005; 97: 103-115
        • Suh C.I.
        • Shanafelt T.
        • May D.J.
        • et al.
        Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.
        Mol Cell Probe. 2000; 14: 211-217
        • Goessl C.
        • Muller M.
        • Heicappell R.
        • et al.
        DNA-based detection of prostate cancer in urine after prostatic massage.
        Urology. 2001; 58: 335-338
        • Hoque M.O.
        • Topaloglu O.
        • Begum S.
        • et al.
        Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
        J Clin Oncol. 2005; 23: 6569-6575
        • Jeronimo C.
        • Usadel H.
        • Henrique R.
        • et al.
        Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.
        J Natl Cancer Inst. 2001; 93: 1747-1752
        • Roupret M.
        • Hupertan V.
        • Yates D.R.
        • et al.
        Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
        Clin Cancer Res. 2007; 13: 1720-1725
        • Krassenstein R.
        • Sauter E.
        • Dulaimi E.
        • et al.
        Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
        Clin Cancer Res. 2004; 10: 28-32
        • Ibanez de Caceres I.
        • Battagli C.
        • Esteller M.
        • et al.
        Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
        Cancer Res. 2004; 64: 6476-6481
        • Muller H.M.
        • Oberwalder M.
        • Fiegl H.
        • et al.
        Methylation changes in faecal DNA: a marker for colorectal cancer screening?.
        Lancet. 2004; 363: 1283-1285
        • Petko Z.
        • Ghiassi M.
        • Shuber A.
        • et al.
        Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
        Clin Cancer Res. 2005; 11: 1203-1209
        • Lofton-Day C.
        • Model F.
        • Devos T.
        • et al.
        DNA methylation biomarkers for blood-based colorectal cancer screening.
        Clin Chem. 2008; 54: 414-423
        • Dulaimi E.
        • Uzzo R.G.
        • Greenberg R.E.
        • et al.
        Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
        Clin Cancer Res. 2004; 10: 1887-1893
        • Friedrich M.G.
        • Weisenberger D.J.
        • Cheng J.C.
        • et al.
        Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
        Clin Cancer Res. 2004; 10: 7457-7465
        • Keller T.
        • Bitterlich N.
        • Hilfenhaus S.
        • et al.
        Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles.
        J Cancer Res Clin Oncol. 1998; 124: 565-574
        • Watine J.
        Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review.
        Scand J Clin Lab Invest. 2000; 60: 259-273
        • Hernandez J.
        • Thompson I.M.
        Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
        Cancer. 2004; 101: 894-904
        • Lilja H.
        • Ulmert D.
        • Vickers A.J.
        Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
        Nat Rev Cancer. 2008; 8: 268-278
        • Lewis C.M.
        • Cler L.R.
        • Bu D.W.
        • et al.
        Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
        Clin Cancer Res. 2005; 11: 166-172
        • Hoque M.O.
        • Feng Q.
        • Toure P.
        • et al.
        Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
        J Clin Oncol. 2006; 24: 4262-4269
        • Duffy M.J.
        • Bonfrer J.M.
        • Kulpa J.
        • et al.
        CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
        Int J Gynecol Cancer. 2005; 15: 679-691
        • Duffy M.J.
        Predictive markers in breast and other cancers: a review.
        Clin Chem. 2005; 51: 494-503
        • Lonning P.E.
        Study of suboptimum treatment response: lessons from breast cancer.
        Lancet Oncol. 2003; 4: 177-185
        • Maier S.
        • Nimmrich I.
        • Koenig T.
        • et al.
        DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
        Eur J Cancer. 2007; 43: 1679-1686
        • Harbeck N.
        • Nimmrich I.
        • Hartmann A.
        • et al.
        Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
        J Clin Oncol. 2008; 26: 5036-5042
        • Nimmrich I.
        • Sieuwerts A.M.
        • Meijer-van Gelder M.E.
        • et al.
        DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
        Breast Cancer Res Treat. 2008; 111: 429-437
        • Hartmann O.
        • Spyratos F.
        • Harbeck N.
        • et al.
        DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer patients treated with adjuvant anthracyclene-based chemotherapy.
        Clin Cancer Res. 2009; 15: 307-314
        • Martens J.W.
        • Nimmrich I.
        • Koenig T.
        • et al.
        Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
        Cancer Res. 2005; 65: 4101-4117
        • Wen P.Y.
        • Kesari S.
        Malignant gliomas in adults.
        New Engl J Med. 2008; 359: 492-507
        • Pegg A.E.
        Repair of O(6)-alkylguanine by alkyltransferases.
        Mutat Res. 2000; 462: 83-100
        • Esteller M.
        • Garcia-Foncillas J.
        • Andion E.
        • et al.
        Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
        New Engl J Med. 2000; 343: 1350-1354
        • Hegi M.E.
        • Diserens A.C.
        • Gorlia T.
        • et al.
        MGMT gene silencing and benefit from temozolomide in glioblastoma.
        New Engl J Med. 2005; 352: 997-1003
        • Widschwendter M.
        • Siegmund K.D.
        • Muller H.M.
        • et al.
        Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.
        Cancer Res. 2004; 64: 3807-3813
        • Esteller M.
        • Gaidano G.
        • Goodman S.N.
        • et al.
        Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
        J Natl Cancer Inst. 2002; 94: 26-32
        • Alaminos M.
        • Davalos V.
        • Cheung N.K.
        • et al.
        Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
        J Natl Cancer Inst. 2004; 96: 1208-1219
        • Shimamoto T.
        • Ohyashiki J.H.
        • Ohyashiki K.
        Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia.
        Leuk Res. 2005; 29: 653-659
        • Bastian P.J.
        • Palapattu G.S.
        • Lin X.
        • et al.
        Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
        Clin Cancer Res. 2005; 11: 4037-4043
        • Rosenbaum E.
        • Hoque M.O.
        • Cohen Y.
        • et al.
        Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
        Clin Cancer Res. 2005; 11: 8321-8325
        • Brabender J.
        • Usadel H.
        • Metzger R.
        • et al.
        Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
        Clin Cancer Res. 2003; 9: 223-227
        • Safar A.M.
        • Spencer 3rd, H.
        • Su X.
        • et al.
        Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.
        Clin Cancer Res. 2005; 11: 4400-4405
        • Brock M.V.
        • Hooker C.M.
        • Ota-Machida E.
        • et al.
        DNA methylation markers and early recurrence in stage I lung cancer.
        N Engl J Med. 2008; 358: 1118-1128
        • Wallner M.
        • Herbst A.
        • Behrens A.
        • et al.
        Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
        Clin Cancer Res. 2006; 12: 7347-7352
        • Kwabi-Addo B.
        • Chung W.
        • Shen L.
        • et al.
        Age-related DNA methylation changes in normal human prostate tissues.
        Clin Cancer Res. 2007; 13: 3796-3802
        • Issa J.P.
        • Ottaviano Y.L.
        • Celano P.
        • et al.
        Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon.
        Nat Genet. 1994; 7: 536-540
        • Frommer M.
        • McDonald L.E.
        • Millar D.S.
        • et al.
        A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.
        Proc Natl Acad Sci USA. 1992; 89: 1827-1831
        • Fraga M.F.
        • Esteller M.
        DNA methylation: a profile of methods and applications.
        Biotechniques. 2002; 33: 636-649
        • Kagan J.
        • Srivastava S.
        • Barker P.E.
        • et al.
        Towards clinical application of methylated DNA sequences as cancer biomarkers: A Joint NCI’s EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools.
        Cancer Res. 2007; 67: 4545-4549
        • Henken F.E.
        • Wilting S.M.
        • Overmeer R.M.
        • et al.
        Sequential gene promoter methylation during HPV-induced cervical carcinogenesis.
        Brit J Cancer. 2007; 97: 1457-1464
        • Herman J.G.
        • Graff J.R.
        • Myohanen S.
        • et al.
        Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
        Proc Natl Acad Sci USA. 1996; 93: 9821-9826
        • Xiong Z.
        • Laird P.W.
        COBRA: a sensitive and quantitative DNA methylation assay.
        Nucleic Acids Res. 1997; 25: 2532-2534
        • Gonzalgo M.L.
        • Jones P.A.
        Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE).
        Nucleic Acids Res. 1997; 25: 2529-2531
        • Gebhard C.
        • Schwarzfischer L.
        • Pham T.H.
        • et al.
        Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR.
        Nucleic Acids Res. 2006; 34: e82
        • Yegnasubramanian S.
        • Lin X.
        • Haffner M.C.
        • et al.
        Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation.
        Nucleic Acids Res. 2006; 34: e19
        • Eads C.A.
        • Danenberg K.D.
        • Kawakami K.
        • et al.
        MethyLight: a high-throughput assay to measure DNA methylation.
        Nucleic Acids Res. 2000; 28: E32
        • Bonanno C.
        • Shehi E.
        • Adlerstein D.
        • et al.
        MS-FLAG, a novel real-time signal generation method for methylation-specific PCR.
        Clin Chem. 2007; 53: 2119-2127
        • Cottrell S.E.
        • Distler J.
        • Goodman N.S.
        • et al.
        A real-time PCR assay for DNA-methylation using methylation-specific blockers.
        Nucleic Acids Res. 2004; 32: e10
        • Uhlmann K.
        • Brinckmann A.
        • Toliat M.R.
        • et al.
        Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis.
        Electrophoresis. 2002; 23: 4072-4079
        • Taylor K.H.
        • Kramer R.S.
        • Davis J.W.
        • et al.
        Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.
        Cancer Res. 2007; 67: 8511-8518
        • Huang T.H.
        • Perry M.R.
        • Laux D.E.
        Methylation profiling of CpG islands in human breast cancer cells.
        Hum Mol Genet. 1999; 8: 459-470
        • Estecio M.R.
        • Yan P.S.
        • Ibrahim A.E.
        • et al.
        High-throughput methylation profiling by MCA coupled to CpG island microarray.
        Genome Res. 2007; 17: 1529-1536
        • Hayashizaki Y.
        • Hirotsune S.
        • Okazaki Y.
        • et al.
        Restriction landmark genomic scanning method and its various applications.
        Electrophoresis. 1993; 14: 251-258
        • Wilson I.M.
        • Davies J.J.
        • Weber M.
        • et al.
        Epigenomics: mapping the methylome.
        Cell Cycle. 2006; 5: 155-158
        • Ballestar E.
        • Paz M.F.
        • Valle L.
        • et al.
        Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.
        Embo J. 2003; 22: 6335-6345
        • Rauch T.
        • Li H.
        • Wu X.
        • et al.
        MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells.
        Cancer Res. 2006; 66: 7939-7947
        • Adorjan P.
        • Distler J.
        • Lipscher E.
        • et al.
        Tumour class prediction and discovery by microarray-based DNA methylation analysis.
        Nucleic Acids Res. 2002; 30: e21
        • Coolen M.W.
        • Statham A.L.
        • Gardiner-Garden M.
        • et al.
        Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements.
        Nucleic Acids Res. 2007; 35: e119
        • Schatz P.
        • Distler J.
        • Berlin K.
        • et al.
        Novel method for high throughput DNA methylation marker evaluation using PNA-probe library hybridization and MALDI-TOF detection.
        Nucleic Acids Res. 2006; 34: e59
        • Sweep F.C.
        • Fritsche H.A.
        • Gion M.
        • et al.
        Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
        Int J Oncol. 2003; 23: 1715-1726
        • Pepe M.S.
        • Etzioni R.
        • Feng Z.
        • et al.
        Phases of biomarker development for early detection of cancer.
        J Natl Cancer Inst. 2001; 93: 1054-1061
        • Pepe M.S.
        • Feng Z.
        • Janes H.
        • et al.
        Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.
        J Natl Cancer Inst. 2008; 100: 1432-1438
        • Foekens J.A.
        • Wang Y.
        • Martens J.W.
        • et al.
        The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
        Drug Discov Today. 2008; 13: 481-487
        • Duffy M.J.
        • Crown J.
        A personalized approach to cancer treatment: how biomarkers can help.
        Clin Chem. 2008; 54: 1770-1779